EyePoint Prelim 2020 Product Revenue, Business Update

 - IND filed in December 2020 for EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration -

- Anticipated Phase 1 clinical trial initiation in Q1 2021 -

- Q4 2020 net product revenues are estimated to be $6.2 - $6.6 million versus $7.9 million in 2019 and $20.3 - $20.7 million for the full year 2020 as compared to $16.8 million for the full year 2019 -

- Sequential quarterly increases in customer demand of 30% and 10% for DEXYCU^® and YUTIQ^®, respectively -

- Approximately $44M of cash and cash equivalents estimated on December 31, 2020 -

https://www.globenewswire.com/news-release/2021/01/11/2156596/0/en/EyePoint-Pharmaceuticals-Provides-Business-Update-and-Preliminary-Fourth-Quarter-and-Full-Year-2020-Net-Product-Revenues.html